Gilead Sciences Inc GILD
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Gilead Sciences Inc is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $179.5B, based in the USA.
It employs about 17,000 people and has been listed since Jan 22, 1992.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Cheap or expensive? priced in line with its group
The company is loss-making, so it has no P/E — we compare on price-to-sales instead.
Its price-to-sales (P/S) is 5.9 versus 5.3 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 10% versus the same quarter last year.
The average analyst price target is 158.65, 10% above the current price (their view, not ours).
The stock sits at 78% of its one-year range (0% = the low, 100% = the high).
The risks
- • The company is loss-making.
- • Net debt is 2.0× shareholders' equity — high leverage.
Strengths
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (1% fewer shares in a year).
- ✅ Most analysts rate it buy (21 vs 1).
- ✅ Pays a dividend (2.2% a year).
What changed this week
Over the past week the stock fell 4.1% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
No notable news about the company was found in the past week.
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.